Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 9,622 calls trading, 2x expected, and implied vol increasing almost 27 ...

Arcutis Biotherapeutics, Inc. (ARQT) shares rallied 15.9% in the last trading session to close at $13.21. This move can be attributable to notable volume with a higher number of shares being traded ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...

Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research report issued on Monday,Benzinga reports. Other equities ...

A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.

New research from the Florida State University Department of Chemistry and Biochemistry shows that a particular type of monoclonal antibody known as NISTmAb retains its structure even if the sugar ...